A Multiaddressable Photochromic Bisthienylethene with Sequence-Dependent Responses: Construction of an INHIBIT Logic Gate and a Keypad Lock

A photochromic bisthienylethene derivative (<b>BIT</b>) containing two imidazole units has been synthesized and fully characterized. When triggered by chemical ions (Ag⁺), protons, and light, <b>BIT</b> can behave as an absorbance switch, leading to a multiaddressable system. <b>BIT</b> exhibits sequence-dependent responses via efficient interaction of the specific imidazole unit with protons and Ag⁺. Furthermore, an INHIBIT logic gate and a keypad lock with three inputs are constructed with the unimolecular platform by employing an absorption mode at different wavelengths as outputs on the basis of an appropriate combination of chemical and photonic stimuli

Dye-Sensitized Solar Cells Based on Quinoxaline Dyes: Effect of π‑Linker on Absorption, Energy Levels, and Photovoltaic Performances

Quinoxaline derivatives show great potential in recent organic photovoltaics, not only as polymer acceptors for bulk heterojuction (BHJ) solar cells but also as molecular sensitizers for dye-sensitized solar cells (DSSCs). This work focuses on the effect of π-linkers on photovoltatic performances of D–A−π–A quinoxaline-based sensitizers used for DSSCs. The extension of π-linkers is one of the viable tactics to improve the molar absorption coefficient and red-shift the absorption peak, which is beneficial to light harvesting. With respect to IQ4, a series of quinoxaline sensitizers IQ6, IQ7, and IQ8 were synthesized on the basis of a promising building block of 2,3-diphenylquinoxaline with π-linker modification. Dye IQ8, with an additional thienyl unit near the anchor group, shows little change in absorption spectra and energy levels, while in IQ6 and IQ7, the additional thienyl group close to the donor group obviously red-shifts the absorption band and positively shifts the HOMO levels. In the series of sensitizers, their adsorption amounts on the TiO2 surface are slightly decreased by introduction of a thienyl unit near the donor part and/or the introduction of alkyl chains. Their photovoltaic performances are well evaluated by the electron collection length values (Lcol), first-principles calculations, the conduction band edge (ECB), and the fluctuation of electron density or charge recombination rate in DSSCs. Instead of the electron injection efficiency (Φinj), the low charge collection efficiency (Φcol) of IQ6, IQ7, and IQ8 results in their unsatisfactory incident photon-to-current conversion efficiency (IPCE) plateaus. Also the difference of Voc among these dyes mainly arises from the fluctuation of TiO2 electron density, which is closely related to the recombination resistance. Upon increasing the thiophene number, the electron collection lengths of IQ6, IQ7, and IQ8 based DSSCs become shorter, which dramatically decreases their photocurrent with an unbeneficial preferable photovoltaic performance. As demonstrated, it is essential to have a judicious design on π-linker modification for high-performance D–A−π–A quinoxaline-based sensitizers

Near-Infrared Colorimetric and Fluorescent Cu²⁺ Sensors Based on Indoline–Benzothiadiazole Derivatives via Formation of Radical Cations

The donor–acceptor system of indoline–benzothiadiazole is established as the novel and reactive platform for generating amine radical cations with the interaction of Cu²⁺, which has been successfully exploited as the building block to be highly sensitive and selective near infrared (NIR) colorimetric and fluorescent Cu²⁺ sensors. Upon the addition of Cu²⁺, an instantaneous red shift of absorption spectra as well as the quenched NIR fluorescence of the substrates is observed. The feasibility and validity of the radical cation generation are confirmed by cyclic voltammetry and electron paramagnetic resonance spectra. Moreover, the introduction of an aldehyde group extends the electron spin density and changes the charge distribution. Our system demonstrates the large scope and diversity in terms of activation mechanism, response time, and property control in the design of Cu²⁺ sensors

Image_1_Association of bevacizumab and stroke in ovarian cancer: a systematic review and meta-analysis.TIF

BackgroundThe prognosis for patients with ovarian cancer is bleak. Clinical trials have shown the efficacy of bevacizumab in ovarian cancer treatment. However, life-threatening strokes may limit the usage of bevacizumab and require specific follow-up strategies. This study aims to systematically evaluate the risk of stroke of bevacizumab treatment in ovarian cancer.MethodsWe retrieved all relevant articles published up to December 4th, 2022, from Embase, PubMed, Web of Science, and the Cochrane Library. The risk of stroke in patients with ovarian cancer treated with bevacizumab combined with chemotherapy was analyzed. Meta-analysis was performed using the Stata 17 software and R 4.2.1 program.ResultsSix randomized controlled trials (RCTs) of bevacizumab combined with chemotherapy or chemotherapy for ovarian cancer and six single-experimental-arm trials were included in this study. The meta-analysis showed a pooled risk ratio (RR) of 2.14 [95% confidence interval (CI): 0.88–7.99] for patients with ovarian cancer treated with bevacizumab combined with chemotherapy. Subgroup analyses showed that the incidence of stroke-related adverse events in the carboplatin + paclitaxel + bevacizumab group was 0.01% (95% CI: 0.00–0.01, p ConclusionsThis meta-analysis indicates that chemotherapy combined with bevacizumab may not increase the incidence of stroke in patients with ovarian cancer. However, stroke-related adverse events may be higher in older patients. Cerebral hemorrhage might cause the incidence of stroke more than cerebral ischemia.Systematic review registrationPROSPERO (CRD42022381003).</p

Image_4_Association of bevacizumab and stroke in ovarian cancer: a systematic review and meta-analysis.TIF

BackgroundThe prognosis for patients with ovarian cancer is bleak. Clinical trials have shown the efficacy of bevacizumab in ovarian cancer treatment. However, life-threatening strokes may limit the usage of bevacizumab and require specific follow-up strategies. This study aims to systematically evaluate the risk of stroke of bevacizumab treatment in ovarian cancer.MethodsWe retrieved all relevant articles published up to December 4th, 2022, from Embase, PubMed, Web of Science, and the Cochrane Library. The risk of stroke in patients with ovarian cancer treated with bevacizumab combined with chemotherapy was analyzed. Meta-analysis was performed using the Stata 17 software and R 4.2.1 program.ResultsSix randomized controlled trials (RCTs) of bevacizumab combined with chemotherapy or chemotherapy for ovarian cancer and six single-experimental-arm trials were included in this study. The meta-analysis showed a pooled risk ratio (RR) of 2.14 [95% confidence interval (CI): 0.88–7.99] for patients with ovarian cancer treated with bevacizumab combined with chemotherapy. Subgroup analyses showed that the incidence of stroke-related adverse events in the carboplatin + paclitaxel + bevacizumab group was 0.01% (95% CI: 0.00–0.01, p ConclusionsThis meta-analysis indicates that chemotherapy combined with bevacizumab may not increase the incidence of stroke in patients with ovarian cancer. However, stroke-related adverse events may be higher in older patients. Cerebral hemorrhage might cause the incidence of stroke more than cerebral ischemia.Systematic review registrationPROSPERO (CRD42022381003).</p

Image_2_Association of bevacizumab and stroke in ovarian cancer: a systematic review and meta-analysis.TIF

BackgroundThe prognosis for patients with ovarian cancer is bleak. Clinical trials have shown the efficacy of bevacizumab in ovarian cancer treatment. However, life-threatening strokes may limit the usage of bevacizumab and require specific follow-up strategies. This study aims to systematically evaluate the risk of stroke of bevacizumab treatment in ovarian cancer.MethodsWe retrieved all relevant articles published up to December 4th, 2022, from Embase, PubMed, Web of Science, and the Cochrane Library. The risk of stroke in patients with ovarian cancer treated with bevacizumab combined with chemotherapy was analyzed. Meta-analysis was performed using the Stata 17 software and R 4.2.1 program.ResultsSix randomized controlled trials (RCTs) of bevacizumab combined with chemotherapy or chemotherapy for ovarian cancer and six single-experimental-arm trials were included in this study. The meta-analysis showed a pooled risk ratio (RR) of 2.14 [95% confidence interval (CI): 0.88–7.99] for patients with ovarian cancer treated with bevacizumab combined with chemotherapy. Subgroup analyses showed that the incidence of stroke-related adverse events in the carboplatin + paclitaxel + bevacizumab group was 0.01% (95% CI: 0.00–0.01, p ConclusionsThis meta-analysis indicates that chemotherapy combined with bevacizumab may not increase the incidence of stroke in patients with ovarian cancer. However, stroke-related adverse events may be higher in older patients. Cerebral hemorrhage might cause the incidence of stroke more than cerebral ischemia.Systematic review registrationPROSPERO (CRD42022381003).</p

DataSheet_1_Imaging-Based Body Fat Distribution in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis.docx

BackgroundWomen with polycystic ovary syndrome (PCOS) are generally considered to be central obese and at higher risks of metabolic disturbances. Imaging methods are the golden standards for detecting body fat distribution. However, evidence based on magnetic resonance imaging (MRI) and computed tomography (CT) is conflicting. This study systematically reviewed the imaging-based body fat distribution in PCOS patients and quantitatively evaluated the difference in body fat distribution between PCOS and BMI-matched controls.MethodsPUBMED, EMBASE, and Web of Science were searched up to December 2019, and studies quantitatively compared body fat distribution by MRI, CT, ultrasound, or X-ray absorptiometry (DXA) between women with PCOS and their BMI-matched controls were included. Two researchers independently reviewed the articles, extract data and evaluated the study quality based on Newcastle-Ottawa Scale (NOS).Results47 studies were included in systematic review and 39 were eligible for meta-analysis. Compared to BMI-matched controls, higher accumulations of visceral fat (SMD 0.41; 95%CI: 0.23-0.59), abdominal subcutaneous fat (SMD 0.31; 95%CI: 0.20-0.41), total body fat (SMD 0.19; 95% CI: 0.06-0.32), trunk fat (SMD 0.47; 95% CI: 0.17-0.77), and android fat (SMD 0. 36; 95% CI: 0.06-0.66) were identified in PCOS group. However, no significant difference was identified in all the above outcomes in subgroups only including studies using golden standards MRI or CT to evaluate body fat distribution (SMD 0.19; 95%CI: -0.04-0.41 for visceral fat; SMD 0.15; 95%CI: -0.01-0.31 for abdominal subcutaneous fat). Moreover, meta-regression and subgroup analyses showed that young and non-obese patients were more likely to accumulate android fat.ConclusionsPCOS women seem to have abdominal fat accumulation when compared with BMI-matched controls. However, MRI- and CT- assessed fat distribution was similar between PCOS and controls, suggesting central obesity may be independent of PCOS. These findings will help us reappraise the relationship between PCOS and abnormal fat deposition and develop specialized lifestyle interventions for PCOS patients.Systematic Review RegistrationPROSPERO, identifier CRD42018102983.</p

Image_3_Association of bevacizumab and stroke in ovarian cancer: a systematic review and meta-analysis.TIF

BackgroundThe prognosis for patients with ovarian cancer is bleak. Clinical trials have shown the efficacy of bevacizumab in ovarian cancer treatment. However, life-threatening strokes may limit the usage of bevacizumab and require specific follow-up strategies. This study aims to systematically evaluate the risk of stroke of bevacizumab treatment in ovarian cancer.MethodsWe retrieved all relevant articles published up to December 4th, 2022, from Embase, PubMed, Web of Science, and the Cochrane Library. The risk of stroke in patients with ovarian cancer treated with bevacizumab combined with chemotherapy was analyzed. Meta-analysis was performed using the Stata 17 software and R 4.2.1 program.ResultsSix randomized controlled trials (RCTs) of bevacizumab combined with chemotherapy or chemotherapy for ovarian cancer and six single-experimental-arm trials were included in this study. The meta-analysis showed a pooled risk ratio (RR) of 2.14 [95% confidence interval (CI): 0.88–7.99] for patients with ovarian cancer treated with bevacizumab combined with chemotherapy. Subgroup analyses showed that the incidence of stroke-related adverse events in the carboplatin + paclitaxel + bevacizumab group was 0.01% (95% CI: 0.00–0.01, p ConclusionsThis meta-analysis indicates that chemotherapy combined with bevacizumab may not increase the incidence of stroke in patients with ovarian cancer. However, stroke-related adverse events may be higher in older patients. Cerebral hemorrhage might cause the incidence of stroke more than cerebral ischemia.Systematic review registrationPROSPERO (CRD42022381003).</p

Data_Sheet_1_Association of bevacizumab and stroke in ovarian cancer: a systematic review and meta-analysis.PDF

BackgroundThe prognosis for patients with ovarian cancer is bleak. Clinical trials have shown the efficacy of bevacizumab in ovarian cancer treatment. However, life-threatening strokes may limit the usage of bevacizumab and require specific follow-up strategies. This study aims to systematically evaluate the risk of stroke of bevacizumab treatment in ovarian cancer.MethodsWe retrieved all relevant articles published up to December 4th, 2022, from Embase, PubMed, Web of Science, and the Cochrane Library. The risk of stroke in patients with ovarian cancer treated with bevacizumab combined with chemotherapy was analyzed. Meta-analysis was performed using the Stata 17 software and R 4.2.1 program.ResultsSix randomized controlled trials (RCTs) of bevacizumab combined with chemotherapy or chemotherapy for ovarian cancer and six single-experimental-arm trials were included in this study. The meta-analysis showed a pooled risk ratio (RR) of 2.14 [95% confidence interval (CI): 0.88–7.99] for patients with ovarian cancer treated with bevacizumab combined with chemotherapy. Subgroup analyses showed that the incidence of stroke-related adverse events in the carboplatin + paclitaxel + bevacizumab group was 0.01% (95% CI: 0.00–0.01, p ConclusionsThis meta-analysis indicates that chemotherapy combined with bevacizumab may not increase the incidence of stroke in patients with ovarian cancer. However, stroke-related adverse events may be higher in older patients. Cerebral hemorrhage might cause the incidence of stroke more than cerebral ischemia.Systematic review registrationPROSPERO (CRD42022381003).</p

Self-Assembly Solid-State Enhanced Red Emission of Quinolinemalononitrile: Optical Waveguides and Stimuli Response

The fluorescence of luminescent emitters is often quenched in the solid state, because of the typical aggregation-caused quenching (ACQ) effect, which is a thorny obstacle to high-performance organic optoelectronic materials. The exploration of solid-state enhanced long wavelength, red-emitting chromophores, especially possessing one-dimensional (1D) assembly features, is of great importance. Interestingly, an excellent solid-state enhanced red emission system (denoted as ED) based on quinolinemalononitrile has been developed via the delicate modification of the conventional ACQ dicyanomethylene-4<i>H</i>-pyran (DCM) derivative (denoted as BD) through crystal engineering. ED exhibits extraordinary self-assembly property in a variety of solvents, even realizing the “waving ribbons” with a length of 6 mm and a diameter of 10 μm. Crystal analysis shows that the CH···π and CH···N supramolecular interactions of ED contribute to the twisted self-assembly solid-state enhanced emission phenomenon. However, for BD, strong face-to-face stacking leads to fluorescence quenching in the solid state. Because of such easy assembly and strong solid-state emission properties, application for optical waveguides of ED is realized with a low optical loss. Stimuli-responsive behavior is also elaborated with color change between orange and red by grinding/fuming or pressing/heating